Illumina announced changes to its organization, including the reshuffling of current employees and new hires, that will take effect on Jan. 1, 2014.
President and CEO Jay Flatley will continue to serve as CEO, but the company will separate the two positions and appoint a new president.
The company is also reorganizing into five business units. Kirk Malloy, currently VP of Customer Solutions, will head the Life Sciences business unit. Tristan Orpin, currently chief commercial officer, will head the Reproductive and Genetic Health business unit. Christian Henry, currently SVP and general manager of the Genomic Solutions business will take over as chief commercial officer.
Rick Klausner, Illumina's chief medical officer, will serve as interim leader of the Oncology business unit. Nick Naclerio will head the Enterprise Informatics business unit, while continuing in his current role as SVP of corporate development. Finally, Illumina's newly created New and Emerging Markets business unit will be headed by Matt Posard, currently SVP and general manager of Illumina's Translational and Consumer Genomics.
Additionally, Greg Heath will move from his position as SVP and general manager of Illumina's Diagnostics business unit to SVP of IVD Development. Bob Ragusa will join the company in December as SVP of Operations.
Quality and Regulatory Affairs will become two separate functions with Regulatory Affairs being folded into IVD Development. Melina Cimler will serve as VP of Quality.
The Genome Analysis Centre in Norwich, UK, has named Mario Caccamo to be its new director.
Caccamo joined TGAC in 2009 as head of bioinformatics, and he became deputy director of science in 2012 and interim director early this year. He has 15 years of experience in algorithms research, including working at the Wellcome Trust Sanger Institute and the European Bioinformatics Institute. While at TGAC, Caccamo's research has focused on wheat and barley genomics research, and he has contributed to the development of new algorithmic approaches to dealing with large biological data sets.
Justin Johnson is now the principal translational genomic scientist at AstraZeneca.
Previously, Johnson was director of bioinformatics, genomic services, and IT at EdgeBio where he was responsible for constructing data analysis pipelines and infrastructure. Other jobs he held prior to that include bioinformatics manager at J. Craig Venter Institute and a project manager at the Institute for Genomic Research.
Fei Lu, previously the CEO of SeqWright, which was bought by GE Healthcare last year, is now an independent consultant. Prior to her position at SeqWright, she was President and CEO of BioWright and general manager of Wilbury Partners.
Genewiz has expanded its European operations, opening Genewiz Germany. The firm has appointed Biserka Bacic-Toplek to sales executive to lead the company's Germany business operations.